 ROCKVILLE, Md., Nov. 09, 2020 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system CNS diseases, today announced regulatory updates for SPN-812 viloxazine hydrochloride for the treatment of attention-deficit hyperactivity disorder ADHD in pediatric patients 6 to 17 years of age, and SPN-830 apomorphine infusion pump for the continuous treatment of motor fluctuations on-off episodes in Parkinsons disease PD. 